News Archives | Aurobindo Pharma USA

Currently Browsing

All News

March 31, 2025


Aurobindo Receives FDA Approval for Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Pantoprazole Sodium for Delayed-Release Oral Suspension, 40 mg. Aurobindo Pharma’s Pantoprazole Sodium for Delayed-Release Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), Protonix for Delayed-Release Oral Suspension […]

March 21, 2025


Aurobindo Receives FDA Approval for Nystatin Cream USP, 100,000 units per gram

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nystatin Cream USP, 100,000 units per gram. Aurobindo Pharma’s Nystatin Cream, are an AB-rated generic equivalent to the reference listed drug (RLD), Nystatin Cream manufactured by Taro Pharmaceuticals Inc., Nystatin Cream are […]

February 27, 2025


Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.025%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.025%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC. Tretinoin Gel are indicated for: […]

January 15, 2025


Aurobindo Pharma Breaks Ground On East Windsor Campus

Aurobindo is building a new 170,000-square-foot building in East Windsor. Aurobindo is building a new 170,000-square-foot building on the Aurobindo campus, a state-of-the art pharmaceutical manufacturing facility on Windsor Center Drive. The new building will join the existing 606,620 square foot Aurobindo building constructed in 2016 and the previously acquired 43,000 square foot Patscenter building […]

January 13, 2025


Aurobindo Receives FDA Approval for Tretinoin Gel USP, 0.01%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Tretinoin Gel USP, 0.01%. Aurobindo Pharma’s Tretinoin Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), Retin-A® Gel manufactured by Bausch Health US, LLC. Tretinoin Gel are indicated for: […]

January 02, 2025


Aurobindo Receives FDA Approval for Glycopyrrolate Oral Solution, 1 mg/5 mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Glycopyrrolate Oral Solution, 1 mg/5 mL. Aurobindo Pharma’s Glycopyrrolate Oral Solution, are an AB-rated generic equivalent to the reference listed drug (RLD), Cuvposa® Oral Solution manufactured by Merz Pharmaceuticals, LLC. Glycopyrrolate Oral […]

December 26, 2024


Aurobindo Receives FDA Approval for Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Deutetrabenazine Tablets, 6 mg, 9 mg, and 12 mg. Aurobindo Pharma’s Deutetrabenazine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Austedo® Tablets manufactured by Teva Branded Pharmaceuticals Products […]

December 12, 2024


Aurobindo Receives FDA Approval for Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Clozapine Orally Disintegrating Tablets, 12.5 mg, 25 mg, 100 mg, 150 mg, and 200 mg. Aurobindo Pharma’s Clozapine Orally Disintegrating Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), […]

November 12, 2024


Aurobindo Receives FDA Approval for Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cimetidine Tablets USP, 200 mg, 300 mg, 400 mg, and 800 mg. Aurobindo Pharma’s Cimetidine Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Tagamet® Tablets manufactured by Glaxosmithkline […]

October 15, 2024


Aurobindo Receives FDA Approval for Metronidazole Gel USP, 1%

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Metronidazole Gel USP, 1%. Aurobindo Pharma’s Metronidazole Gel, are an AB-rated generic equivalent to the reference listed drug (RLD), METROGEL® manufactured by Galderma Laboratories, L.P. Metronidazole Gel are indicated for: The topical […]

September 27, 2024


Aurobindo Receives FDA Approval for Cephalexin Tablets USP, 250 mg and 500 mg

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Cephalexin Tablets USP, 250 mg and 500 mg. Aurobindo Pharma’s Cephalexin Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Keflet Tablets manufactured by Eli Lilly and Company. Cephalexin […]

September 26, 2024


Aurobindo Receives FDA Approval for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL

East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. Aurobindo Pharma’s Mycophenolate Mofetil for Oral Suspension, are an AB-rated generic equivalent to the reference listed drug (RLD), CELLCEPT® Oral Suspension manufactured by Roche […]